ADVANCES IN THERAPY is a prestigious peer-reviewed journal published by SPRINGER, specializing in the diverse fields of medicine and pharmacology. Established in 1984, this influential journal has become an essential resource for researchers and professionals, boasting a commendable impact factor and categorically ranking within the Q1 quartile in both Medicine (Miscellaneous) and Medical Pharmacology as of 2023. With an impressive Scopus ranking at #52 out of 272 in the realm of medical pharmacology, it places itself in the top 81st percentile, underscoring its importance in advancing therapeutic knowledge and practices. Although the journal is not open access, it provides invaluable insights and the latest research findings in therapies that significantly impact patient care, making it a vital reference for clinicians, academicians, and students alike.

Ophthalmic Research, with ISSN 0030-3747 and E-ISSN 1423-0259, is a distinguished peer-reviewed journal published by Karger in Switzerland. Established in 1970, this journal serves as a vital resource for exploration and dissemination of knowledge within the fields of Ophthalmology, Cellular and Molecular Neuroscience, and Sensory Systems, maintaining its relevance through its convergence into modern research methodologies leading up to 2024. With impressive rankings in 2023, it holds a Q2 quartile in both Ophthalmology and Medicine (miscellaneous), reflecting its significant contribution to the academic community, alongside Scopus ranks that position it favorably in the competitive landscape of medical and neuroscientific literature. Although not open access, the journal ensures that high-quality research remains accessible to its readership, which includes researchers, professionals, and students eager to stay at the forefront of ophthalmic advancements. By fostering interdisciplinary collaboration and facilitating high-level discourse, Ophthalmic Research is pivotal for those committed to advancing the future of eye care and vision sciences.

PROGRESS IN RETINAL AND EYE RESEARCH, published by PERGAMON-ELSEVIER SCIENCE LTD, is a premier journal dedicated to the advancement of knowledge in the fields of ophthalmology and sensory systems. With an impressive impact factor and a Q1 category ranking in both Ophthalmology and Sensory Systems as of 2023, this journal exemplifies excellence in research dissemination. Given its stature, it ranks #1 out of 137 in Ophthalmology and #1 out of 42 in Neuroscience - Sensory Systems, placing it within the top percentile of scientific publications in these domains. The journal has been actively contributing to the field since its inception in 1994 and continues to be a vital resource for researchers, clinicians, and students seeking the latest insights and breakthroughs in the understanding of retinal diseases and eye health. While it maintains a traditional subscription model, the journal remains committed to publishing high-quality, peer-reviewed articles that drive forward the frontiers of eye research and therapeutic innovation. With its strong scientific rigor and a vast array of articles, PROGRESS IN RETINAL AND EYE RESEARCH is indispensable for anyone invested in the study of visual sciences.

Welcome to Pulmonary Pharmacology & Therapeutics, a leading journal dedicated to the dissemination of innovative research and insights in the fields of pulmonary medicine and pharmacology. Published by Academic Press Ltd - Elsevier Science Ltd, this journal has made significant contributions to the academic community since its inception in 1997, with an ongoing commitment to relevant advancements projected through to 2024. With reputable Q2 rankings across vital categories including Biochemistry (medical), Medicine (miscellaneous), Pharmacology (medical), and Pulmonary and Respiratory Medicine, Pulmonary Pharmacology & Therapeutics is ranked in the top tier of its field, reflecting its impact on the discipline as evidenced by its Scopus rankings. Researchers, healthcare professionals, and students alike can access a wealth of high-quality articles that address the complexity of pulmonary diseases and therapeutic strategies, supporting research and clinical practice alike. Join the vibrant community contributing to this essential field and explore the latest findings that can drive change in patient care and therapeutic effectiveness.

Translational Vision Science & Technology is a premier open access journal dedicated to the advancement of the field of ophthalmology and biomedical engineering. Published by the Association for Research in Vision and Ophthalmology, Inc., this journal has established itself as a leading source of high-quality research since its inception in 2013, achieving a remarkable impact factor reflective of its influential contribution to the field. With an impressive ranking of #21 in Ophthalmology and #120 in Biomedical Engineering within the Scopus database, it sits within the prestigious Q1 quartile for both categories as of 2023, further validating its significance. The journal's scope encompasses a wide variety of topics focused on the intersection of ophthalmological science and technological innovation, welcoming contributions that promote the understanding and treatment of visual disorders. Available as an Open Access publication since 2016, it ensures that cutting-edge research is freely accessible to researchers, practitioners, and students worldwide, facilitating the rapid dissemination of knowledge essential for the advancement of vision science.

ANTI-CANCER DRUGS is a leading journal in the domain of cancer research and pharmacology, published by Lippincott Williams & Wilkins. With its inception dating back to 1990 and ongoing publication through 2024, this journal serves as a vital resource for researchers, clinicians, and students interested in the latest advancements and discoveries in cancer therapeutics. Although classified in the Q3 quartile across relevant categories such as Cancer Research and Oncology, its growing impact is evidenced by its competitive Scopus rankings, positioned within the 30th to 52nd percentiles across various disciplines. The journal remains committed to promoting innovative research that can translate into effective anti-cancer strategies, providing valuable insights into drug development and applications. While it does not currently offer open access, the journal continues to attract a sophisticated readership, making it an essential platform for disseminating significant findings in the ever-evolving field of oncology.

Welcome to the International Journal of Pharmacology, a key publication in the field of pharmacology, published by ASIAN NETWORK SCIENTIFIC INFORMATION (ANSINET). Since its inception in 2006, this journal has provided a vital platform for researchers and professionals to disseminate their findings and insights in pharmacology, toxicology, and pharmaceutics. Despite recent discontinuation in Scopus coverage, the journal's dedication to fostering scientific dialogue continues to attract contributions from esteemed scholars globally. With an **ISSN of 1811-7775** and **E-ISSN of 1812-5700**, the journal seeks to bridge the gap between laboratory research and clinical application, promoting a deeper understanding of drug actions and interactions. Although it operates under traditional access options, the relevance of its published studies to ongoing pharmacological research remains significant.

CLINICAL PHARMACOLOGY & THERAPEUTICS, published by WILEY, stands at the forefront of pharmacological research, serving as a pivotal resource for researchers, healthcare professionals, and students in the medical field. With its prestigious Q1 rating in both Pharmacology and Pharmacology (medical) categories, and ranking in the top 4% of journals in the field, it provides cutting-edge insights into drug therapy, pharmacokinetics, and innovative treatment strategies. The journal features a wide range of articles, from original research to comprehensive reviews, all aimed at advancing knowledge and clinical practice in pharmacology. With a publication history dating back to 1960 and continuing through 2024, its commitment to excellence is evident in its robust impact factor and high visibility in the academic community. For professionals striving to stay at the forefront of pharmacological advancements, CLINICAL PHARMACOLOGY & THERAPEUTICS remains an essential platform for disseminating and accessing vital research findings.

Drug Discoveries and Therapeutics is a highly regarded journal devoted to the advancement of knowledge in the field of medicine and pharmacology. Published by the International Research & Cooperation Association for Biological & Socio-Sciences Advancement in Tokyo, Japan, this journal serves as a vital resource for researchers, practitioners, and students interested in the latest developments in drug discovery and therapeutic strategies. With a Scopus ranking of #192 out of 826 in the General Medicine category, and positioning itself in the 76th percentile, it demonstrates a significant impact within the scientific community. The journal publishes original research articles, reviews, and innovative studies that address the complexities of drug development, therapeutic efficacy, and clinical applications. Researchers and clinicians can access valuable insights to enhance their practices and inform further studies as it continues to disseminate crucial findings essential for the advancement of medical science.

JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, published by LIPPINCOTT WILLIAMS & WILKINS, is a leading peer-reviewed journal dedicated to the exploration and advancement of pharmacological therapies related to cardiovascular diseases. With its ISSN 0160-2446 and E-ISSN 1533-4023, this esteemed journal has been at the forefront of cardiovascular research since its inception in 1979, continuously offering insights until 2024. It holds a commendable position in the 2023 category quartiles, classified as Q2 in both Cardiology and Cardiovascular Medicine, as well as Medicine (miscellaneous) and Pharmacology, showcasing its significance within these fields. The journal presents a unique platform for researchers, health professionals, and students to disseminate their findings, fostering an environment of knowledge growth and collaboration in cardiovascular pharmacology. Readers can expect to find high-quality articles that contribute to the body of knowledge in cardiovascular therapies, ensuring they remain informed of the latest advancements and clinical practices. Discover more about this influential publication and its commitment to enhancing cardiovascular health.